VSTM Verastem
- 12.1300
- -0.9900-7.55%
- 12.7300
- +0.6000+4.95%
Verastem News
Buy Rating Affirmed for Verastem Amid Positive Developments and Strong Financial Position
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), ANI Pharmaceuticals (ANIP) and Argenx Se (ARGX)
Express News | HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $17.5 Price Target
Verastem Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 47.68% HC Wainwright & Co. → $17.5 Reiterates Buy → Buy 03/19/2024 47.68% HC Wainwright & Co. →
Buy Rating on Verastem: Promising Pipeline and Regulatory Milestones Drive Positive Outlook
RBC Capital Sticks to Their Buy Rating for Verastem (VSTM)
Verastem Inc. Poised for Growth: Buy Rating Affirmed on Clinical and Regulatory Milestones
Express News | Verastem Q1 2024 GAAP EPS $(1.26) Misses $(0.94) Estimate
Express News | Verastem Inc: Qtrly Adj Shr Loss $0.98
Verastem | 10-Q: Quarterly report
Express News | Verastem Q1 Net Income USD -33.863 Million
Express News | Verastem Q1 Operating Expenses USD 28.059 Million
Verastem 1Q Loss $33.9M >VSTM
Verastem 1Q Loss $33.9M >VSTM
Press Release: Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates Plan to announce topline RAMP 201 data with the start of planned rolling NDA submission for avuto
Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the first quarter ended March 31, 2024.
Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 2024 RBC
Express News | Verastem Oncology Announces Appointment of John Hayslip, M.d., to Chief Medical Officer
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Laboratory (LH) and Longboard Pharmaceuticals (LBPH)
VS-6766 Drug Research 2024: Developed by Verastem Oncology, An RAF/MEK Clamp That Induces Inactive Complexes of MEK With ARAF, BRAF, and CRAF - Market Size, Forecast, and Emerging Insights 2019-2032
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Verastem (VSTM)
Analysis
Price Target
No Data
